GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenwich LifeSciences Inc (NAS:GLSI) » Definitions » ROE %

Greenwich LifeSciences (Greenwich LifeSciences) ROE % : -141.30% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Greenwich LifeSciences ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Greenwich LifeSciences's annualized net income for the quarter that ended in Dec. 2023 was $-10.99 Mil. Greenwich LifeSciences's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $7.78 Mil. Therefore, Greenwich LifeSciences's annualized ROE % for the quarter that ended in Dec. 2023 was -141.30%.

The historical rank and industry rank for Greenwich LifeSciences's ROE % or its related term are showing as below:

GLSI' s ROE % Range Over the Past 10 Years
Min: -89.3   Med: -27.94   Max: -14.18
Current: -87

During the past 6 years, Greenwich LifeSciences's highest ROE % was -14.18%. The lowest was -89.30%. And the median was -27.94%.

GLSI's ROE % is ranked worse than
70.59% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs GLSI: -87.00

Greenwich LifeSciences ROE % Historical Data

The historical data trend for Greenwich LifeSciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenwich LifeSciences ROE % Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - -14.18 -16.79 -39.08 -89.30

Greenwich LifeSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.00 -68.28 -58.31 -98.12 -141.30

Competitive Comparison of Greenwich LifeSciences's ROE %

For the Biotechnology subindustry, Greenwich LifeSciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenwich LifeSciences's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenwich LifeSciences's ROE % distribution charts can be found below:

* The bar in red indicates where Greenwich LifeSciences's ROE % falls into.



Greenwich LifeSciences ROE % Calculation

Greenwich LifeSciences's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-8.892/( (13.214+6.7)/ 2 )
=-8.892/9.957
=-89.30 %

Greenwich LifeSciences's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-10.988/( (8.853+6.7)/ 2 )
=-10.988/7.7765
=-141.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Greenwich LifeSciences  (NAS:GLSI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-10.988/7.7765
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.988 / 0)*(0 / 8.0725)*(8.0725 / 7.7765)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0381
=ROA %*Equity Multiplier
=N/A %*1.0381
=-141.30 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-10.988/7.7765
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.988 / -10.988) * (-10.988 / -11.344) * (-11.344 / 0) * (0 / 8.0725) * (8.0725 / 7.7765)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9686 * N/A % * 0 * 1.0381
=-141.30 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Greenwich LifeSciences ROE % Related Terms

Thank you for viewing the detailed overview of Greenwich LifeSciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenwich LifeSciences (Greenwich LifeSciences) Business Description

Traded in Other Exchanges
N/A
Address
3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells in order to inhibit the spread of cancer.
Executives
Snehal Patel director, officer: CHIEF EXECUTIVE OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Jaye Thompson officer: VPC AND REGULATORY AFFAIRS 2408 TIMBERLOCH PLACE, B-7, THE WOODLANDS TX 77380
Frank Joseph Daugherty director, officer: CHIEF MEDICAL OFFICER 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kenneth Hallock director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
David Mcwilliams director 2575 WEST BELLFORT STREET, HOUSTON TX 77054-9816
Eric Rothe director 2311 SPARTAN TRAIL, SUGAR LAND TX 77479
Kinnary Patel 10 percent owner 3992 BLUEBONNET DR., BUILDING 14, STAFFORD TX 77477
Panjaj Amrit Patel 10 percent owner 50726 LAKESIDE DRIVE, GRANGER IN 46530